Ryvu Therapeutics Presents Preclinical Data on RVU305, ONCO Prime, and Next-Generation ADCs at AACR and ADC Payload Summit
Read More
Ryvu Therapeutics announces dosing of the first patient in the JASPIS-01 Phase II Study of dapolsertib (MEN1703/SEL24) for the Treatment of r/r DLBCL
Read More
Ryvu Therapeutics to present preclinical data on synthetic lethality at the 2025 AACR Annual Meeting
Read More
Ryvu Therapeutics Reports 2024 Fiscal Year Financials
Read More
Ryvu Therapeutics announces strategic reorganization to extend the cash runway for the development of RVU120 and the preclinical pipeline
Read More
Ryvu Therapeutics awarded two grants to support next-generation ADCs development
Read More
